GT Biopharma (GTBP) Stock Forecast & Price Target

$2.81 +1.07 (+61.03%)

(As of 05:45 PM ET)

GT Biopharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Strong Buy

Based on 2 Analyst Ratings

Sell
0

Hold
0

Buy
2

Based on 2 Wall Street analysts who have issued ratings for GT Biopharma in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 1 has given a buy rating, and 1 has given a strong buy rating for GTBP.

Consensus Price Target

$11.00
291.46% Upside

According to the 2 analysts' twelve-month price targets for GT Biopharma, the average price target is $11.00. The highest price target for GTBP is $11.00, while the lowest price target for GTBP is $11.00. The average price target represents a forecasted upside of 291.46% from the current price of $2.81.

Get the Latest News and Ratings for GTBP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GT Biopharma and its competitors.

GTBP Analyst Ratings Over Time

Type	Current Forecast 12/24/23 to 12/23/24	1 Month Ago 11/24/23 to 11/23/24	3 Months Ago 9/25/23 to 9/24/24	1 Year Ago 12/24/22 to 12/24/23
Strong Buy	1 Strong Buy rating(s)	N/A	N/A	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	N/A	N/A	1 Buy rating(s)
Hold	0 Hold rating(s)	N/A	N/A	1 Hold rating(s)
Sell	0 Sell rating(s)	N/A	N/A	0 Sell rating(s)
Consensus Price Target	$11.00	N/A	N/A	$105.00
Forecasted Upside	291.46% Upside	N/A	N/A	1,245.12% Upside
Consensus Rating	Strong Buy	N/A	N/A	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

GTBP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GTBP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GT Biopharma Stock vs. The Competition

Type	GT Biopharma	Medical Companies	S&P 500
Consensus Rating Score	3.50	2.81	2.51
Consensus Rating	Strong Buy	Moderate Buy	Moderate Buy
Predicted Upside	291.46% Upside	25,625.71% Upside	14.28% Upside
News Sentiment Rating	Positive News See Recent GTBP News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/2/2024	Roth Capital 2 of 5 stars	J. Aschoff Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/2/2024	Roth Mkm 1 of 5 stars		Initiated Coverage	Buy	$11.00	+292.86%
8/8/2023	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$150.00	+1,685.71%
3/31/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold	$60.00	+330.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:39 PM ET.

GTBP Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for GT Biopharma is $11.00, with a high forecast of $11.00 and a low forecast of $11.00.
: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There is currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" GTBP shares.
: According to analysts, GT Biopharma's stock has a predicted upside of 291.46% based on their 12-month stock forecasts.
: Over the previous 90 days, GT Biopharma's stock had 1 upgrade by analysts.
: GT Biopharma has been rated by research analysts at Roth Capital, and Roth Mkm in the past 90 days.
: Analysts like GT Biopharma more than other "medical" companies. The consensus rating for GT Biopharma is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GTBP compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

No one’s talking about these Trump trades (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

This page (NASDAQ:GTBP) was last updated on 12/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Stock Forecast & Price Target